^
    Back
    Association details:
    Biomarker:MTOR A2034V
    Cancer:Breast Cancer
    Drug:RapaLink-1 (mTOR inhibitor, mTORC1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nature
    Title:

    Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

    Published date:
    06/09/2016
    Excerpt:
    Mouse xenografts of MCF-7 cells expressing the RR1 mutant A2034V mTOR showed significantly less sensitivity to rapamycin yet maintained full sensitivity to AZD8055 and RapaLink-1 treatment.
    DOI:
    10.1038/nature17963